Regeneron Pharmaceuticals ((REGN)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals and Sanofi are conducting an observational study titled A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care. The study aims to understand the real-world application of DUPIXENT® (dupilumab) in treating patients with eosinophilic esophagitis (EoE), focusing on patient experiences and outcomes.
The intervention being tested is the drug dupilumab, marketed as DUPIXENT®. It is used as a standard treatment for EoE, aiming to alleviate symptoms and improve the quality of life for patients.
This study is designed as an observational cohort with a prospective time perspective, meaning it will follow a group of patients over time to observe outcomes without manipulating the treatment. The primary goal is to gather data on the effectiveness and impact of DUPIXENT® in everyday clinical settings.
The study began on October 30, 2024, with a primary completion date set for three years later. The latest update was submitted on August 28, 2025. These dates are crucial as they mark the progression of the study and its current recruiting status.
The ongoing study could influence Regeneron and Sanofi’s market positions by providing valuable insights into DUPIXENT®’s effectiveness, potentially boosting investor confidence and impacting stock performance. As the pharmaceutical industry closely watches developments in EoE treatments, this study could also affect competitive dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.